Pericapsular Nerve Group (PENG) Block on Postoperative Pain Management After Acetabular Fracture Fixation

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity of Puerto Rico

About this trial

The goal of this clinical trial is to find out whether a Pericapsular Nerve Group (PENG) block, a type of nerve block used to control pain, can reduce pain after surgery in adults with an acetabular (hip socket) fracture who are undergoing surgical repair. The study will also evaluate the safety of the PENG block.

The main questions this study aims to answer are:

Does a PENG block reduce pain after surgery? Does a PENG block reduce the need for opioid pain medications after surgery? Are there any side effects or complications related to the PENG block? Researchers will compare patients who receive a PENG block with patients who do not receive a PENG block to determine whether the block improves pain control after surgery.

Participants will:

Be randomly assigned to receive either a PENG block or no PENG block before surgery while under general anesthesia.

Undergo surgery to repair their acetabular fracture. Receive the same standard pain medications after surgery. Be asked to rate their pain at several time points after surgery using a standard pain scale.

Have their use of pain medications, recovery, and any side effects recorded during their hospital stay and follow-up.

Eligibility criteria

Qualifiers

Patient age 18 years or older

Acetabular Fracture amenable to surgery through the Kocher-Langenbeck approach

Full weight-bearing capacity prior to the trauma

Providing written informed consent

Disqualifiers

Age less than 18 years old

Fracture pattern not amenable to surgery through Kocher-Langenbeck approach

Lower extremity fracture ipsilateral to the acetabular fracture

Any traumatic injury that requires surgical management by other surgical specialty

Trial design

Treatments tested in this trial

  • Pericapsular nerve group (PENG) block

Treatment groups

70 Participants
are divided into 2 treatment groups

Sponsors and collaborators